Krista Fendrick, PA
Psychiatric/Mental Health · Mission Viejo, CANPI 1316297286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 598 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $7,483, more than ten times the $61 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$993
- plus $5K from 20 others
What the payments were for
- Travel & lodging$150%
- Food & beverage$13,73997%
- Education$4523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 93 | $2,360 |
| Teva Pharmaceuticals USA, Inc. | 110 | $2,208 |
| AbbVie(2 entities) | 83 | $1,562 |
| Vanda Pharmaceuticals Inc. | 41 | $1,247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $1,011 |
| Axsome Therapeutics, Inc. | 33 | $993 |
| Alkermes, Inc. | 33 | $938 |
| Otsuka America Pharmaceutical, Inc. | 29 | $806 |
| E.r. Squibb & Sons, L.L.C. | 24 | $708 |
| Johnson & Johnson | 21 | $609 |
| Lundbeck LLC | 23 | $440 |
| Noven Therapeutics, LLC | 22 | $376 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $186 |
| Supernus Pharmaceuticals, Inc. | 9 | $179 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $123 |
| Harmony Biosciences LLC | 1 | $90 |
| Biogen | 3 | $80 |
| Luye Pharma (USA) Ltd. | 2 | $42 |
| Bausch Health US, LLC | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Acadia Pharmaceuticals Inc | 1 | $35 |
| Corium, LLC | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$914
- ARISTADA$468
- INGREZZA$386
- Auvelity$362
- Fanapt$250
- VRAYLAR$245
- INVEGA SUSTENNA$150
- CAPLYTA$130
- UZEDY$126
- REXULTI$120
- ARISTADA INITIO$117
- Austedo XR$111
How this compares
$14,205 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 46 | $348,583 |
| Austedo XrDeutetrabenazine | 13 | $168,958 |
| VraylarCariprazine Hcl | 50 | $79,461 |
| RexultiBrexpiprazole | 43 | $70,234 |
| UzedyRisperidone | 17 | $56,006 |
| TrintellixVortioxetine Hydrobromide | 78 | $52,651 |
| Invega SustennaPaliperidone Palmitate | 12 | $41,550 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,004 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $10,993 |
| Aripiprazole | 184 | $8,408 |
| Bupropion XlBupropion Hcl | 177 | $6,960 |
| BelsomraSuvorexant | 13 | $6,659 |
| Trazodone Hcl | 285 | $6,362 |
| DayvigoLemborexant | 17 | $5,522 |
| Quetiapine Fumarate | 254 | $4,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,360 | $348,58346 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $2,208 | $224,96330 claims |
| AbbVieVraylar | $1,562 | $79,46150 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $806 | $70,23443 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $186 | $63,64493 claims |
| Johnson & JohnsonInvega Sustenna | $609 | $41,55012 claims |
| Axsome Therapeutics, Inc.Auvelity | $993 | $12,00412 claims |
| Lilly USA, LLCOlanzapine | $39 | $2,342109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Mission Viejo
- Sarah KantelisMission Viejo$25K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.